Annual accounts receivable:
$7.42B+$316.00M(+4.45%)Summary
- As of today (May 21, 2025), NVS annual accounts receivable is $7.42 billion, with the most recent change of +$316.00 million (+4.45%) on December 31, 2024.
- During the last 3 years, NVS annual accounts receivable has fallen by -$582.00 million (-7.27%).
- NVS annual accounts receivable is now -28.09% below its all-time high of $10.32 billion, reached on December 31, 2011.
Performance
NVS Accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly accounts receivable:
$8.60B+$1.17B(+15.80%)Summary
- As of today (May 21, 2025), NVS quarterly accounts receivable is $8.60 billion, with the most recent change of +$1.17 billion (+15.80%) on March 31, 2025.
- Over the past year, NVS quarterly accounts receivable has increased by +$756.00 million (+9.64%).
- NVS quarterly accounts receivable is now -21.25% below its all-time high of $10.91 billion, reached on June 30, 2011.
Performance
NVS Quarterly accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Accounts receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
NVS Accounts receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +4.5% | +9.6% |
| 3 y3 years | -7.3% | +2.2% |
| 5 y5 years | -10.6% | +0.6% |
NVS Accounts receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -8.0% | +4.5% | -6.5% | +26.1% |
| 5 y | 5-year | -10.6% | +4.5% | -6.5% | +26.1% |
| alltime | all time | -28.1% | +130.0% | -21.3% | +166.3% |
NVS Accounts receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $8.60B(+15.8%) |
| Dec 2024 | $7.42B(+4.4%) | $7.42B(-6.8%) |
| Sep 2024 | - | $7.97B(-3.2%) |
| Jun 2024 | - | $8.23B(+4.9%) |
| Mar 2024 | - | $7.84B(+10.3%) |
| Dec 2023 | $7.11B(-11.9%) | $7.11B(+4.2%) |
| Sep 2023 | - | $6.82B(-25.8%) |
| Jun 2023 | - | $9.20B(+3.1%) |
| Mar 2023 | - | $8.92B(+10.5%) |
| Dec 2022 | $8.07B(+0.8%) | $8.07B(-4.2%) |
| Sep 2022 | - | $8.42B(-2.6%) |
| Jun 2022 | - | $8.64B(+2.8%) |
| Mar 2022 | - | $8.41B(+5.0%) |
| Dec 2021 | $8.01B(-2.6%) | $8.01B(-4.4%) |
| Sep 2021 | - | $8.38B(-0.3%) |
| Jun 2021 | - | $8.40B(+1.6%) |
| Mar 2021 | - | $8.27B(+0.6%) |
| Dec 2020 | $8.22B(-1.0%) | $8.22B(+1.8%) |
| Sep 2020 | - | $8.07B(+5.6%) |
| Jun 2020 | - | $7.64B(-10.5%) |
| Mar 2020 | - | $8.54B(+2.9%) |
| Dec 2019 | $8.30B(-4.9%) | $8.30B(+6.1%) |
| Sep 2019 | - | $7.83B(-1.8%) |
| Jun 2019 | - | $7.97B(+4.7%) |
| Mar 2019 | - | $7.61B(-12.8%) |
| Dec 2018 | $8.73B(+1.5%) | $8.73B(+1.7%) |
| Sep 2018 | - | $8.59B(-2.5%) |
| Jun 2018 | - | $8.80B(-1.3%) |
| Mar 2018 | - | $8.92B(+3.7%) |
| Dec 2017 | $8.60B(+4.9%) | $8.60B(+1.4%) |
| Sep 2017 | - | $8.48B(+1.2%) |
| Jun 2017 | - | $8.38B(+1.8%) |
| Mar 2017 | - | $8.23B(+0.4%) |
| Dec 2016 | $8.20B(+0.3%) | $8.20B(-4.0%) |
| Sep 2016 | - | $8.55B(-0.7%) |
| Jun 2016 | - | $8.61B(+1.7%) |
| Mar 2016 | - | $8.46B(+3.5%) |
| Dec 2015 | $8.18B(-1.1%) | $8.18B(-3.7%) |
| Sep 2015 | - | $8.49B(-2.9%) |
| Jun 2015 | - | $8.75B(-0.5%) |
| Mar 2015 | - | $8.79B(+6.3%) |
| Dec 2014 | $8.28B(-16.4%) | $8.28B(-6.6%) |
| Sep 2014 | - | $8.86B(-5.5%) |
| Jun 2014 | - | $9.37B(-9.2%) |
| Mar 2014 | - | $10.32B(+4.3%) |
| Dec 2013 | $9.90B | $9.90B(-5.7%) |
| Sep 2013 | - | $10.50B(-2.7%) |
| Jun 2013 | - | $10.79B(+2.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2013 | - | $10.48B(+4.3%) |
| Dec 2012 | $10.05B(-2.6%) | $10.05B(-4.4%) |
| Sep 2012 | - | $10.52B(+0.3%) |
| Jun 2012 | - | $10.49B(-1.1%) |
| Mar 2012 | - | $10.61B(+2.7%) |
| Dec 2011 | $10.32B(+4.6%) | $10.32B(-3.6%) |
| Sep 2011 | - | $10.70B(-1.9%) |
| Jun 2011 | - | $10.91B(+0.5%) |
| Mar 2011 | - | $10.86B(+10.0%) |
| Dec 2010 | $9.87B(+18.8%) | $9.87B(-5.0%) |
| Sep 2010 | - | $10.39B(+33.3%) |
| Jun 2010 | - | $7.80B(+0.3%) |
| Mar 2010 | - | $7.77B(-6.5%) |
| Dec 2009 | $8.31B(+18.3%) | $8.31B(+6.3%) |
| Sep 2009 | - | $7.82B(+9.1%) |
| Jun 2009 | - | $7.17B(+6.2%) |
| Mar 2009 | - | $6.75B(-3.9%) |
| Dec 2008 | $7.03B(+5.7%) | $7.03B(-3.1%) |
| Sep 2008 | - | $7.25B(+1.5%) |
| Jun 2008 | - | $7.14B(+3.8%) |
| Mar 2008 | - | $6.88B(+3.5%) |
| Dec 2007 | $6.65B(+7.9%) | $6.65B(-2.4%) |
| Sep 2007 | - | $6.81B(+9.3%) |
| Jun 2007 | - | $6.23B(-1.9%) |
| Mar 2007 | - | $6.35B(+3.1%) |
| Dec 2006 | $6.16B(+15.3%) | $6.16B(+1.2%) |
| Sep 2006 | - | $6.09B(+3.4%) |
| Jun 2006 | - | $5.88B(+11.2%) |
| Mar 2006 | - | $5.29B(-1.0%) |
| Dec 2005 | $5.34B(+10.1%) | $5.34B(+4.0%) |
| Sep 2005 | - | $5.14B(+0.9%) |
| Jun 2005 | - | $5.09B(+4.8%) |
| Mar 2005 | - | $4.86B(+0.1%) |
| Dec 2004 | $4.85B(+10.9%) | $4.85B(+8.0%) |
| Sep 2004 | - | $4.49B(+0.2%) |
| Jun 2004 | - | $4.48B(+3.6%) |
| Mar 2004 | - | $4.33B(-1.1%) |
| Dec 2003 | $4.38B(+18.4%) | $4.38B(+2.9%) |
| Sep 2003 | - | $4.25B(-0.1%) |
| Jun 2003 | - | $4.26B(+8.4%) |
| Mar 2003 | - | $3.93B(+6.2%) |
| Dec 2002 | $3.70B(+14.5%) | $3.70B(+0.9%) |
| Sep 2002 | - | $3.66B(+1.4%) |
| Jun 2002 | - | $3.61B(+11.9%) |
| Dec 2001 | $3.23B(-1.4%) | $3.23B(-31.7%) |
| Jun 2001 | - | $4.73B(+44.4%) |
| Dec 2000 | $3.27B(-26.0%) | $3.27B |
| Dec 1999 | $4.42B(+4.6%) | - |
| Dec 1998 | $4.23B | - |
FAQ
- What is Novartis AG annual accounts receivable?
- What is the all time high annual accounts receivable for Novartis AG?
- What is Novartis AG annual accounts receivable year-on-year change?
- What is Novartis AG quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Novartis AG?
- What is Novartis AG quarterly accounts receivable year-on-year change?
What is Novartis AG annual accounts receivable?
The current annual accounts receivable of NVS is $7.42B
What is the all time high annual accounts receivable for Novartis AG?
Novartis AG all-time high annual accounts receivable is $10.32B
What is Novartis AG annual accounts receivable year-on-year change?
Over the past year, NVS annual accounts receivable has changed by +$316.00M (+4.45%)
What is Novartis AG quarterly accounts receivable?
The current quarterly accounts receivable of NVS is $8.60B
What is the all time high quarterly accounts receivable for Novartis AG?
Novartis AG all-time high quarterly accounts receivable is $10.91B
What is Novartis AG quarterly accounts receivable year-on-year change?
Over the past year, NVS quarterly accounts receivable has changed by +$756.00M (+9.64%)